Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003450 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003450: Completed Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
NCT00003450 is a Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003450, a Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. PURPOSE: Phase I trial to study the effectiveness of gene therapy using the p53 gene in treating patients with advanced recurrent or persistent ovarian cancer or primary peritoneal cavity cancer.
Interventions
- BIOLOGICAL Ad5CMV-p53 gene
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-09 |
| Est. Completion | 1999-01 |
| Phase | Phase 1 |
What the finished NCT00003450 record still lists
NCT00003450 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Ad5CMV-p53 gene is the first listed.
NCT00003450 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003450 about?
NCT00003450 is a clinical study titled "Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer". RATIONALE: Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. PURPOSE: Phase I trial to study the effectiveness of gene therapy using the p53 gene in treating patients with advanced recurrent or persi...
What is the current status of trial NCT00003450?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-09. Estimated completion is 1999-01.
What interventions are being tested in trial NCT00003450?
The interventions under investigation include: Ad5CMV-p53 gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003450?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia